Results 111 to 120 of about 3,536 (218)

A new drug for an old concept: aptamer to von Willebrand factor for prevention of arterial and microvascular thrombosis

Haematologica, 2020
Agnès Veyradier
doaj   +1 more source

The evolving therapeutic landscape of spinal muscular atrophy – A scoping review of investigational agents, emerging delivery technologies and strategic innovations

British Journal of Clinical Pharmacology, Volume 92, Issue 6, Page 1552-1566, June 2026.
Spinal muscular atrophy (SMA) is a severe neuromuscular disease with emerging therapeutic complexity. This review aims to systematically map the global pipeline of investigational treatments for SMA. Using ClinicalTrials.gov and complementary international registries, we identified 21 planned or ongoing interventional trials from 2020 to 2025 targeting
Andrej Belančić, Patrick Eustaquio, Elvira Meni Maria Gkrinia, Ivana Stević, Eugen Javor, Yun Wah Lam, Slobodan Janković, Dinko Vitezić   +7 more
wiley   +1 more source

Methotrexate Toxicity in a Patient With Renal Failure Despite a Normal Methotrexate Concentration: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Methotrexate (MTX) is a folate antagonist widely used as a disease‐modifying antirheumatic drug (DMARD) in rheumatoid arthritis (RA), as well as in several malignancies and autoimmune disorders. Although low‐dose MTX (5–20 mg/week) is generally considered safe, it has a narrow therapeutic index, and toxicity can occur even at therapeutic doses,
Fatemeh Afra, Mahshad Ghoddusi, Mahsa Mottahedi, Maryam Albaji, Samira Kafan, Roya Saedpanah, Amir Shokri, Elham Nazar   +7 more
wiley   +1 more source

Catastrophic Antiphospholipid Syndrome in a Young Female Complicated by Systemic Lupus Erythematosus and Left Atrial Myxoma: A Rare Case Report

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Catastrophic antiphospholipid syndrome (CAPS) is a fulminant and rare variant of antiphospholipid syndrome characterized by rapidly progressive multiorgan thrombosis and a high mortality rate. Its diagnosis is often challenging due to overlapping clinical features with sepsis, thromboembolic disorders, and systemic autoimmune diseases.
Nazmin Ahmed, Mohammad Nazrul Hossain, Abdullah Salman, Sabrina Yesmin, S. M. G. Saklayen   +4 more
wiley   +1 more source

Clinical Scoring Systems in Thrombotic Microangiopathies

, 2017
Thrombotic microangiopathies (TMAs) are a group of rare but potentially lethal hematologic disorders characterized by platelet-rich thrombi in the microvasculature.
Lova Sun, Robert Makar, Vivek Upadhyay, Marisa Marques, Pavan Bendapudi   +4 more
core   +1 more source

Diagnosing Syndrome‐Like Microangiopathic Hemolytic Anemia After Pit Viper Envenomation: Overcoming Laboratory Gaps in a Resource‐Limited Setting: A Case Report From Nepal

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Snakebite envenomation remains a significant yet often overlooked health challenge in Nepal, particularly in its rural and hilly regions. While venom‐induced consumption coagulopathy (VICC) is commonly observed with viper bites, microangiopathic hemolytic anemia (MAHA) is an extremely rare complication, especially with green pit vipers ...
Prabhat Kaphle, Pukar Gupta, Sarjan Shrestha, Neeru Diyali, Raj Kumar Koirala, Amrita Shrestha, Dhanlaxmi Giri, Nabin Pahari, Anil Kumar Sah, Kamal Hamal, Sujan Bohara   +10 more
wiley   +1 more source

Pregnancy-related thrombotic microangiopathies: Clues from complement biology

, 2016
International audiencePregnancy is a high-risk period for various types of thrombotic microangiopathies (TMA). The improvement of our understanding of the pathophysiology of TMAs has translated into better management of pregnancy-related TMAs.
Fakhouri, Fadi, Fakhouri, F., Fadi Fakhouri   +2 more
core   +1 more source

Shifting From Systemic to Precision‐Targeted Complement Therapies: Opportunities and Hurdles

European Journal of Immunology, Volume 56, Issue 6, June 2026.
Complement therapeutics have expanded considerably, but systemic inhibitors remain limited by infection risks, breakthrough events, and loss of physiological functions. Emerging targeted approaches aim for organ‐, tissue‐, or cell‐specific modulation of complement activity, potentially offering greater precision while reducing treatment burden and ...
Marco Mannes, Wioleta M. Zelek, Leendert A. Trouw   +2 more
wiley   +1 more source

Etiology and outcomes: Thrombotic microangiopathies in pregnancy. [PDF]

Res Pract Thromb Haemost, 2023
Scully M, Neave L.
europepmc   +1 more source

Therapeutic Plasma Exchange in the Elderly: Rare Indications but Good Tolerability

Journal of Clinical Apheresis, Volume 41, Issue 3, June 2026.
ABSTRACT Therapeutic plasma exchange (TPE) is used for a wide range of indications and is associated with well‐described adverse events. However, no study has specifically focused on tolerance in elderly patients, despite its expected increasing use in this population. We conducted a single‐center retrospective case–control study of all patients aged ≥ 
Valentin Coirier, Quentin Quelven, Pauline Guillot, Elie Jalaber, Floriane L’Her, Vincent Joussellin, Félicie Bélicard, Kieran Pinceaux, Adel Maamar, Mathieu Lesouhaitier, Jean‐Marc Tadié, Nicolas Terzi   +11 more
wiley   +1 more source